Effect of Zofa (Nepeta bracteata Benth.) Product on Chronic Obstructive Pulmonary Disease

Effect of Zofa (Nepeta bracteata Benth.) Product on Spirometric Parameters and Respiratory Symptoms in the Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015121925598N1

Enrollment

Registered

2016-03-24

Start date

2016-04-02

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstractive Pulmonary Disease. Other specified chronic obstructive pulmonary disease

Interventions

Intervention 1: Zofa Product (Syrup),Oral, 10cc, Three times of day for four weeks. Intervention 2: Placebo Product (Syrup), Oral. 10 cc, Three times a day for four weeks.

Treatment - Drugs

Placebo

Zofa Product (Syrup),Oral, 10cc, Three times of day for four weeks

Placebo Product (Syrup), Oral. 10 cc, Three times a day for four weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 139 Years

Inclusion criteria

Inclusion criteria: Including criteria: Mild to Moderate Chronic Obstructive Pulmonary Disease; Age 18 and more; no allergy to the Lamiaceae family; no lactation or pregnancy; not having Diabetes and history of epilepsy and seizure Excluding criteria: Exacerbation period

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Evaluation of quality of life of patients. Timepoint: The time of study inclusion and two and four weeks later. Method of measurement: COPD Assessment Test (CAT) Questionnair.;Chenge of FEV1 (Forced Expiratory volume in 1 second). Timepoint: Before treatment and four weeks after treatment. Method of measurement: Spirometry super Spiro, Micro medical company, England.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Abdolahinia

Shahed University

aaliabd@yahoo.com; aaliabd@gmail.com; abdolahinia@sbmu.ac.ir+98 21 5121 4056

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026